Granahan Investment Management Inc. MA acquired a new position in Akcea Therapeutics Inc (NASDAQ:AKCA) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 308,211 shares of the company’s stock, valued at approximately $8,528,000. Granahan Investment Management Inc. MA owned 0.46% of Akcea Therapeutics at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Candriam Luxembourg S.C.A. bought a new stake in shares of Akcea Therapeutics in the 3rd quarter worth approximately $5,314,000. OxFORD Asset Management LLP bought a new stake in shares of Akcea Therapeutics in the 3rd quarter worth approximately $6,872,000. Strs Ohio bought a new stake in shares of Akcea Therapeutics in the 3rd quarter worth approximately $118,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Akcea Therapeutics in the 3rd quarter worth approximately $180,000. Finally, Legal & General Group Plc bought a new stake in shares of Akcea Therapeutics in the 3rd quarter worth approximately $111,000. Institutional investors own 26.04% of the company’s stock.

Akcea Therapeutics Inc (NASDAQ AKCA) opened at $18.61 on Tuesday. Akcea Therapeutics Inc has a twelve month low of $8.10 and a twelve month high of $31.23.

A number of brokerages have commented on AKCA. Zacks Investment Research upgraded Akcea Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 9th. Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 price objective (up previously from $19.00) on shares of Akcea Therapeutics in a research report on Tuesday, November 7th. Finally, Cowen reiterated a “buy” rating on shares of Akcea Therapeutics in a research report on Tuesday, October 31st. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $24.00.

COPYRIGHT VIOLATION NOTICE: “Granahan Investment Management Inc. MA Invests $8.53 Million in Akcea Therapeutics Inc (AKCA)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/12/granahan-investment-management-inc-ma-invests-8-53-million-in-akcea-therapeutics-inc-akca.html.

Akcea Therapeutics Company Profile

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).

Institutional Ownership by Quarter for Akcea Therapeutics (NASDAQ:AKCA)

Receive News & Stock Ratings for Akcea Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics Inc and related stocks with our FREE daily email newsletter.